怡达股份(300721) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥371.73 million, a decrease of 1.26% compared to ¥376.47 million in the same period last year[5]. - The net loss attributable to shareholders was ¥25.32 million, representing a decline of 160.95% from a profit of ¥41.54 million in the previous year[5]. - The basic earnings per share were -¥0.2952, a decrease of 211.69% compared to ¥0.2643 in the same period last year[5]. - The net cash flow from operating activities was -¥44.96 million, a decline of 90.97% from -¥22.45 million in the previous year[5]. - Total operating revenue for Q1 2023 was CNY 371,729,418.45, a decrease of 1.98% compared to CNY 376,474,274.66 in the same period last year[24]. - Net profit for Q1 2023 was a loss of CNY 31,227,212.78, compared to a profit of CNY 41,204,126.92 in Q1 2022[25]. - The total comprehensive income attributable to the parent company was -25,315,240.76 CNY, compared to 41,536,972.63 CNY in the previous period[26]. - Cash flow from operating activities showed a net outflow of -42,864,151.66 CNY, compared to -22,445,055.31 CNY in the previous period[29]. Asset and Liability Management - The total assets at the end of the reporting period were ¥2.81 billion, a decrease of 1.55% from ¥2.86 billion at the end of the previous year[5]. - The company's total assets decreased to CNY 2,811,116,607.58 from CNY 2,855,320,515.43, a decline of 1.55%[23]. - The company's total liabilities decreased slightly to CNY 1,551,169,716.93 from CNY 1,553,597,834.70, a reduction of 0.16%[23]. Cash Flow Analysis - The company reported a net cash outflow of ¥68.40 million, an increase of 114.34% compared to -¥31.91 million in the previous year[10]. - The company's cash and cash equivalents decreased to CNY 279,439,277.37 from CNY 321,028,202.26 at the beginning of the year, reflecting a decline of 12.93%[21]. - The cash and cash equivalents at the end of the period were 198,611,672.48 CNY, compared to 125,860,956.79 CNY at the end of the previous period[29]. - The total cash inflow from financing activities was 250,000,000.00 CNY, down from 354,500,000.00 CNY in the previous period[29]. - The net cash flow from financing activities was 63,754,011.90 CNY, compared to 111,573,462.04 CNY in the previous period[29]. - The total cash outflow from investing activities was 89,116,486.44 CNY, down from 120,968,468.38 CNY in the previous period[29]. Sales and Market Performance - The average selling price of ether and ether ester products decreased by 26.97% year-on-year, leading to a 13.44% drop in gross profit margin[11]. - The sales volume of ether and ether ester products increased by 16.43% year-on-year, indicating a growth in market share despite revenue decline[11]. - The company reported a decrease in sales revenue from 374,937,769.21 CNY to 351,064,353.80 CNY[28]. - Total operating costs increased significantly to CNY 417,621,740.49, up 28.66% from CNY 324,728,635.84 in the previous year[24]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 13,966[12]. - The top 10 shareholders hold a combined 43.69% of the shares, with Liu Zhun holding the largest share at 21.05% (34,295,684 shares)[12]. - Liu Zhun has 3,363,000 shares pledged, while other top shareholders have no pledged shares[12]. - The number of shares with limited sale conditions for Liu Zhun increased to 25,721,763 shares due to capital reserve conversion[15]. - The top 10 unrestricted shareholders include Shen Guixiu with 20,235,980 shares and Liu Zhaoxuan with 9,908,500 shares[12]. - The total number of restricted shares at the end of the period is 27,576,612 shares, with significant increases due to capital reserve conversion[17]. - Liu Zhun's restricted shares increased by 12,183,993 shares during the reporting period[15]. - The company has no preferred shareholders as of the reporting period[14]. - The company’s major shareholders have familial relationships, indicating potential influence on decision-making[12]. Operational Insights - The company experienced a significant increase in management expenses, rising by 289.75% to ¥49.52 million due to increased shutdown losses[9]. - Research and development expenses for Q1 2023 were CNY 7,735,131.30, an increase from CNY 5,699,263.32 in the previous year, reflecting a growth of 35.69%[25]. - The company plans to leverage the production of propylene oxide and extend into downstream industries to improve profitability[11]. - The company’s subsidiary, Taixing Yida, obtained a safety production license valid from February 17, 2023, to February 16, 2026[18].